Mesoblast could need another COVID trial says CEO
MELBOURNE: Losses at stem cell treatments producer Mesoblast have hit $US98.8 million ($135 million) for
MELBOURNE: Losses at stem cell treatments producer Mesoblast have hit $US98.8 million ($135 million) for
FEATURED
Test hope for early action on dementia research advance
New elderly hub to be ‘exemplar’ of care for future
Best nursing home design for Global Awards shortlisted
Health app start-ups race raises concerns with GPs
Seniors housing operators must embrace healthcare-based models
Investor survey and trends report into seniors living & care published
INNOVATION
